GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Operating Margin %

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Operating Margin % : 0.00% (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Anthera Pharmaceuticals's Operating Income for the three months ended in Mar. 2018 was $-10.97 Mil. Anthera Pharmaceuticals's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Therefore, Anthera Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2018 was 0.00%.

The historical rank and industry rank for Anthera Pharmaceuticals's Operating Margin % or its related term are showing as below:


ANTH's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -168.78
* Ranked among companies with meaningful Operating Margin % only.

Anthera Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Anthera Pharmaceuticals's Operating Income for the three months ended in Mar. 2018 was $-10.97 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2018 was $-36.70 Mil.


Anthera Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Anthera Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Operating Margin % Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1,106.53 -39,432.41 -

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anthera Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Anthera Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Operating Margin % falls into.



Anthera Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Anthera Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2017 is calculated as

Operating Margin %=Operating Income (A: Dec. 2017 ) / Revenue (A: Dec. 2017 )
=-36.432 / 0
= %

Anthera Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2018 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2018 ) / Revenue (Q: Mar. 2018 )
=-10.971 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals  (OTCPK:ANTH) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Anthera Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines